Literature DB >> 15659459

Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study.

Gang Chen1, Wenyao Lin, Fumin Shen, Uchenna H Iloeje, W Thomas London, Alison A Evans.   

Abstract

BACKGROUND: Studies of chronic hepatitis B virus (HBV) infection in endemic populations have rarely documented causes of mortality other than liver disease and hepatocellular carcinoma (HCC).
METHODS: We analysed all-cause mortality related to HBV infection, focusing on the deaths not related to liver disease in a prospective cohort of adults living in Haimen City, China, who were followed from 1992 to 2002. Death certificate data from 4590 deaths among 83 794 individuals were analysed. At cohort entry, 15.0% of the 58 454 male subjects and 10.7% of 25 340 female subjects were hepatitis B surface antigen positive [HbsAg(+)]. HCC and chronic liver disease were the major causes of death in both men and women in this population. The analysis focused on non-liver causes of death.
RESULTS: When liver-related causes of death were excluded, there was still a significantly higher age-adjusted death rate among HBsAg(+) individuals. The relative risks (RRs) and 95% confidence intervals (CIs) for all non-liver deaths among HBsAg(+) subjects were 1.2 (1.1-1.3) in men and 1.4 (1.1-1.7) in women. Non-liver causes were further subdivided into cancer and non-cancer groups. For all non-liver cancers, the RR was 1.2 (1.0-1.4) for males and 1.7 (1.2-2.3) for females. Non-liver, non-cancer deaths had RRs of 1.2 (1.1-1.4) and 1.2 (0.9-1.6) in males and females, respectively.
CONCLUSIONS: HBV-infected individuals may be at increased mortality risk from non-liver causes. Possible reasons include a direct effect of HBV infection, changes in the host immune system as a cause or effect of chronic infection, and behavioural factors associated with HBV infection. Further studies are needed to confirm this finding.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15659459     DOI: 10.1093/ije/dyh339

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  15 in total

1.  Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand.

Authors:  Siwaporn Chainuvati; Jun Cheng; Jin Lin Hou; Chao Wei Hsu; Ji Dong Jia; Piyawat Komolmit; So Young Kwon; Chang Hong Lee; Hong Li; Ying Li; Chun Jen Liu; Boon Leong Neo; Cheng Yuan Peng; Tawesak Tanwandee; Suchat Wongcharatrawee; Jaw Ching Wu; Ming Lung Yu; Xin Xin Zhang
Journal:  Hepatol Int       Date:  2009-06-24       Impact factor: 6.047

2.  Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies.

Authors:  George Lau; Patrick Marcellin; Marion Peters
Journal:  Hepatol Int       Date:  2007-06-06       Impact factor: 6.047

3.  Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy.

Authors:  Toshifumi Tada; Takashi Kumada; Hidenori Toyoda; Seiki Kiriyama; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Shusuke Kitabtake; Takanori Ito
Journal:  J Gastroenterol       Date:  2014-11-07       Impact factor: 7.527

4.  Five-year review of HIV-hepatitis B virus (HBV) co-infected patients in a New York City AIDS center.

Authors:  Jong Hun Kim; George Psevdos; Victoria Sharp
Journal:  J Korean Med Sci       Date:  2012-06-29       Impact factor: 2.153

5.  Are physicians following guidelines? A survey of Hepatitis B management strategies.

Authors:  Keat Hong Lee; Myat Oo Aung; Seng Gee Lim
Journal:  Hepatol Int       Date:  2012-10-06       Impact factor: 6.047

6.  Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients.

Authors:  Ji-Dong Jia; Jin-Lin Hou; You-Kuan Yin; De-Ming Tan; Daozhen Xu; Jun-Qi Niu; Xia-Qiu Zhou; Yu-Ming Wang; Li-Min Zhu; Cheng-Wei Chen; Yong-Wen He; Hong Ren; Mo-Bin Wan; Shan-Ming Wu; Qin-Huan Wang; Lai Wei; Weibin Bao; Yuhong Dong; Aldo Trylesinski
Journal:  Hepatol Int       Date:  2013-11-28       Impact factor: 6.047

7.  Treating chronic hepatitis B virus: Chinese physicians' awareness of the 2010 guidelines.

Authors:  Lai Wei; Ji-Dong Jia; Xin-Hua Weng; Xiao-Guang Dou; Jia-Ji Jiang; Hong Tang; Qin Ning; Qing-Qing Dai; Run-Qin Li; Jie Liu
Journal:  World J Hepatol       Date:  2016-06-28

8.  In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.

Authors:  Lung-Yi Mak; Sze-Hang Liu; Desmond Yat-Hin Yap; Wai-Kay Seto; Danny Ka-Ho Wong; James Fung; Tak-Mao Chan; Ching-Lung Lai; Man-Fung Yuen
Journal:  Dig Dis Sci       Date:  2019-07-06       Impact factor: 3.199

9.  Cancer risk in HBV patients with statin and metformin use: a population-based cohort study.

Authors:  Chang-I Chen; Ching-Feng Kuan; Yu-Ann Fang; Shing-Hwa Liu; Ju-Chi Liu; Li-Li Wu; Chun-Jen Chang; Hsuan-Chia Yang; Jaulang Hwang; James S Miser; Szu-Yuan Wu
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

Review 10.  Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures.

Authors:  Masahiro Tanaka; Francisco Katayama; Hideaki Kato; Hideo Tanaka; Jianbing Wang; You Lin Qiao; Manami Inoue
Journal:  J Epidemiol       Date:  2011-10-22       Impact factor: 3.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.